[Edaily Reporter Kim Hyung-il ] HanWool Materials Science, Inc.(091440)has signed a 3.5 billion won contract with KTCorporation(030200)to build a disaster safety communications network. The contract value exceeds 26% of last year’s revenue.
HanWool Materials Science, Inc. CI. (Photo courtesy of HanWool Materials Science, Inc.)
According to the Financial Supervisory Service’s electronic disclosure system on the 12th, HanWool Materials Science, Inc. announced that it had signed a contract with KTCorporation for the construction of the 2026 Disaster Safety Communication Network in Project Areas A and B (PTN). The contract amount is 3.55513 billion won, which represents 26.46% of last year’s consolidated revenue of 13.43507 billion won.
This contract combines two separate contracts for the construction of Project Areas A and B. Specifically, the contract for Project Area A is worth 1.991 billion won, and the contract for Project Area B is worth 1.564 billion won. KTCorporation is the counterparty for both contracts, and the contract dates are the same.
The contract period runs through November 30 of next year. The project area is within South Korea, and HanWool Materials Science, Inc. will carry out the work using its own production methods. Payment will be made in cash.
The contractual warranty period for defects is 36 months following final acceptance. The contract amount excludes value-added tax (VAT), and both the contract term and amount are subject to change based on consultations with KTCorporation and other factors.
“The key point in the Jensen Huang scandal will ultimately be that data centers were built in China and elsewhere, and cloud services were provided to Chinese companies. Given the circumstances, this …
#The BORN Korea announced on the 13th that it posted a consolidated operating loss of 3.7 billion won in the third quarter of this year. This represents an improvement in the loss compared to the same…
Resolute announced to the U.S. Securities and Exchange Commission (SEC) on the 14th (local time) that it had completed patient enrollment for the Phase 3 clinical trial of “Ersodetug.” (Source: U.S. S…
